Heparin, which is traditionally used as an anticoagulant but has a variety of additional biological activities, was shown in several retrospective and prospective clinical trials to have an effect on cancer survival. Experimental evidence from animal models consistently demonstrates that heparin is an efficient inhibitor of metastasis. To clarify the mechanism of heparin antimetastatic activity, several biological effects are being investigated. Cancer progression and metastasis are associated with enhanced expression of heparanase, which is inhibited efficiently by heparin. Heparin is also a potent inhibitor of selectin-mediated interactions. P-and L-selectin were shown to contribute to the early stages of metastasis, which is associated with platelet-tumor cell thrombi formation. To delineate the biological activities of heparin contributing to metastasis inhibition, modified heparins with specific activities were evaluated. Low anticoagulant heparin preparations still inhibited metastasis efficiently, indicating that anticoagulation is not a necessary component for heparin attenuation of metastasis. Modified heparins characterized for heparanase inhibitory activity are also potential inhibitors of selectins. Selectin inhibition is a clear component of heparin inhibition of metastasis. The contribution of selectin or heparanase inhibition by heparin can provide evidence about its antimetastatic activity.
The effect of heparin on cancer progression has been reported both in human cancer and in experimental models since the early 1960s. Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are used for anticoagulant treatment of cancer patients suffering from concurrent thromboembolic complications. 1 On the basis of encouraging observations from several retrospective studies, in which prolonged survival of cancer patients treated with heparin has been observed, several recent prospective clinical trials have been performed to evaluate this phenomenon. [2] [3] [4] [5] [6] Despite the use of different protocols among these clinical trials, heparin treatment was proven to be beneficial for patients, especially those with a better prognosis at the beginning of the study. Given that the LMWH therapy lasts only for a limited time, the overall increase of patient survival over an extended period cannot be attributed primarily to its anticoagulant activity. 6 Thus, the favorable effect of a brief course of LMWH treatment merits additional clinical evaluation.
HEPARIN ATTENUATES EXPERIMENTAL METASTASIS
Many mouse studies of the effect of heparin on metastasis have been reported. When a variety of tumor cells were used, including human and mouse colon carcinoma and melanoma, mouse lung carcinoma, and mouse breast carcinoma, UFH and various LMWHs were shown to attenuate metastasis in mouse models. [7] [8] [9] The experimental metastasis model, in which tumor cells are administered directly into the blood, is often used to study the effect of heparins on this process. This model enables evaluation of the effect of a treatment at specific time points, and narrows the number of interactions being affected by the treatment. A single injection of UFH as well as LMWHs was shown to attenuate metastasis of mouse melanoma cells. [10] [11] [12] [13] [14] Studies with colon carcinoma cells using a single bolus of UFH before intravenous tumor cell injection resulted in attenuation of metastasis. 15, 16 In most cases, the doses of UFH and LMWH used in these studies were several times higher than the currently acceptable doses in humans. However, attenuation of metastasis was also achieved at clinically relevant doses of heparins with both colon carcinoma and melanoma cells. 17, 18 Thus, injection of heparin shortly before tumor cell injection attenuated metastasis, whereas heparin treatment more than 24 hours before or after tumor cell injection did not affect this process. 7, 11, 14 Taken together, the data from the animal models strongly suggest that heparin reduces metastasis, and the relevant mechanism of action is the current focus of investigation in several laboratories.
POTENTIAL MECHANISM(S) OF HEPARIN EFFECT ON METASTASIS
Heparin is a complex mixture of glycosaminoglycans isolated from porcine mucosa. 19 It is a linear polysaccharide composed of alternating derivatives of D-glucosamine and uronic acid with various degrees of sulfation. The structure of heparin determines its biological activities, several of which have the potential to be involved directly in attenuation of cancer progression and metastasis. Heparin contains, among others, the following activities: (1) anticoagulant, (2) tissue factor pathways inhibitor release, (3) heparanase inhibition, (4) selectinmediated interaction inhibition, (5) angiogenesis inhibition, (6) modulation of the activity of some proteases and extracellular matrix components, and (7) growth factor binding. 1, 7, 9, 20 All of these give heparin the potential to modulate the mitogenic properties of cells.
By the evaluation of experimental data, some of these activities can be determined to be less likely than others to play a role in metastasis. In the experimental metastasis model, tumor cells are injected directly into circulation, thus their contact with blood cells and/or endothelium is likely one of the earliest events in this process. Given that the administered heparin is cleared from circulation within a few hours, the transient effects of heparin on angiogenesis and binding of growth factors are likely not relevant in this early phase. 15 In addition, studies with the synthetic pentasaccharide fondaparinux, which serves as an anticoagulant but does not share many of heparin's other activities, did not show any effect on metastasis, indicating that anticoagulation is not critical in heparin attenuation of metastasis, 17 an idea further supported by work involving heparins with little or no anticoagulant activity, which will be discussed in a later section.
Conversely, many of heparin's activities have been shown to be relevant for attenuation of metastasis. Several laboratories are investigating the role of cell-cell interactions mediated by the selectins and the involvement of heparanase in metastasis. Heparin was shown to bind to P-and L-selectin efficiently. 21, 22 In addition, heparin efficiently inhibited P-and L-selectin-mediated interactions with cancer cells in various in vitro and in vivo experiments. [14] [15] [16] 23, 24 Inhibition of heparanase activity with heparin was also shown to affect metastasis. 11, 25 The enhanced expression of heparanase in mammary adenocarcinomas, lymphomas, and melanomas is causally associated with increased invasiveness and metastasis.
11,26,27 UFH or LMWH treatment attenuated metastasis by inhibition of heparanase in experimental metastasis of human and rat mammary carcinoma and mouse melanoma.
26,28

SELECTIN DEPENDENCE OF METASTASIS
The entrance of invasive carcinomas into the blood circulation makes these cells potential candidates for interactions with the blood constituents (endothelium, platelets, and leukocytes), which are often mediated by selectins. Selectins are vascular cell adhesion molecules involved in adhesive interactions of leukocytes, platelets, and endothelium within the blood circulation. The initial steps in leukocyte tethering and rolling on endothelium are supported by rapid and reversible interactions of selectins with their carbohydrate ligands. The role of selectins has been elucidated in selectin-deficient mouse models. In addition to their well-known physiological functions during hemostasis, selectins (P-, L-, and E-selectin) are initiating cell adhesion molecules in the vasculature, making selectin-mediated interactions with blood-borne carcinomas possible. P-selectin is present in the storage granules of endothelial cells (Weibel-Palade bodies) and platelets (a-granules), thus enabling its rapid exteriorization on cell surfaces upon activation. 29 Almost all leukocyte subpopulations carry L-selectin constitutively on their cell surfaces. Although upregulation of E-selectin in the liver was shown to divert metastasis from the lungs to the liver, its delayed cell-surface expression upon activation suggests that E-selectin may not be critical for the very early steps of naturally occurring metastatic processes. 30 The remainder of this discussion, therefore, will focus only on P-and L-selectin.
Hematogenous metastasis is the commonest route of cancer spread for epithelial neoplasms (carcinomas). Carcinomas contains large amount of mucins, carrying terminal carbohydrate structures such as sialyl Lewis x/a (sLe x/a ), the core ligand for the selectins. 31 The relationship between sLe x expression and decreased survival has been shown for a variety of cancers, including gastric cancer, 32 prostate cancer, 33 and breast cancer. 34, 35 The common association of sLe x/a expression with poor prognosis for cancer patients supports the proposed hypothesis that selectins facilitate metastasis.
In the context of metastasis initiation, the rapid nature of P-selectin expression upon activation of endothelia or platelets, together with the constant presence of L-selectin on leukocytes, makes these selectins potential candidates for contribution to metastasis. The possible involvement of P-and L-selectin in metastasis was studied in mice deficient either in individual P-or L-selectin or in double P/L-selectindeficient mice. [14] [15] [16] 36 Although the absence of P-or L-selectin significantly attenuated metastasis of carcinoma cells, there was virtually no metastasis observed in the P/L double-deficient mice (PL-sel À / À ), strongly suggesting a synergistic effect of both selectins in this process. 16 Heparin was shown to bind to P-and L-selectin efficiently, despite the lack of obvious structural similarity to the natural selectin ligands such as sLe x/a . 21, 22 Although the exact heparin structure recognized by P-and L-selectin is not known, the biological activity of heparin is likely explained by the dense cluster of multiple negatively charged sulfates and carboxylates, which mimics the natural ligand. Nevertheless, heparin efficiently inhibited P-and L-selectin-mediated interactions with cancer cells in various in vitro and in vivo experiments. 14, 15, 23, 36, 37 Heparin injection 30 minutes before tumor cell injection attenuated metastasis in wild-type mice to similar levels as observed in P-selectin-deficient mice (P-sel À / À ). [14] [15] [16] However, no additional attenuation of metastasis could be observed in P-sel À / À mice injected with heparin prior to tumor cell injection. In L-selectin-deficient mice, injection of heparin 30 minutes prior to injection of tumor cells attenuated metastasis further, suggesting that the L-selectin-mediated involvement of leukocytes is independent of P-selectin-mediated platelet aggregation. No additional reduction of metastasis in PL-sel À / À indicated that no other biological activity of heparin was actively contributing to attenuation of metastasis.
Tumor cell emboli, formed by platelets and leukocytes, have been associated with potentiation of tumor metastasis. 38 Intravenous injection of tumor cells in mice is mostly associated with platelet-fibrin aggregates, whereas the absence of platelet-tumor cell interactions leads to clearance of tumor cells by natural killer cells. 39, 40 Although an exact molecular mechanism of platelet-tumor cell complex formation is not characterized completely, considerable evidence suggests that P-selectin is one of the mediators in this process. 15 P-selectin deficiency leads to reduced platelet-tumor cell interactions and tumor cell seeding to the lung vasculature. 15, 36 Elimination of selectin ligands from tumor cells reduced platelet aggregation, subsequently leading to reduced metastasis. Finally, platelet-tumor cell aggregation was effectively blocked by heparin injection, leading to reduced retention of cancer cells in the lung vasculature with subsequent attenuation of metastasis. 15 Studies evaluating the role of L-selectin in metastasis indicated that leukocytes contribute to this process in a time period subsequent to P-selectin-dependent platelet interactions. 36 Heparin injection several hours after the tumor cells were introduced into the vasculature led to attenuation of metastasis, primarily due to L-selectin inhibition.
Altogether, currently available data allow the conclusion that the effect of heparin on metastasis in mice is time dependent. The rather short presence of heparin in blood circulation in these studies, along with the strong attenuation of metastasis in injected mice, emphasizes the significant role of this short-term interaction.
MODIFIED HEPARINS ARE EFFICIENT INHIBITORS OF METASTASIS
To differentiate heparin's anticoagulant activity from its other activities, several laboratories have prepared chemically modified heparins. Heparins with minimal or no anticoagulant activity were prepared by various methods. 11, [40] [41] [42] [43] [44] [45] These heparin preparations were tested in mouse models of experimental metastasis with mouse lung carcinoma and melanoma cells (Table 1) . Despite large variation in the heparin dosage used in various laboratories, injection of heparins with limited anticoagulant activity in a time period around the tumor cell injection (shortly before or after) was associated with reduction of metastasis. The single exception was the study by Lapierre et al, 42 in which a lower concentration of modified heparin injected 1 hour prior to the injection of tumor cells did not reduce metastasis. When low anticoagulant heparin (LAC heparin) was injected intravenously, attenuation of metastasis was observed, whereas subcutaneous injection did not alter metastasis. 44 Thus the presence of heparin in circulation is required for its metastatic activity.
However, the characterization of these modified heparins was only limited, thereby enabling significant variation in their biological activities with respect to mechanism of heparin anti-metastatic activity. LAC heparin was shown to affect tubular formation of endothelial cells and migration of tumor cells in vitro 43 and modified heparins were evaluated for their heparanase inhibitory activity. 42 Indeed, specific desulfation of 2-Oand 6-O-sulfate on glucosamine enhanced heparanase inhibitory activity and limited its anticoagulant activity. 11, 42, 46 Given that heparanase expression clearly correlated with metastatic potential of cancer cells in vivo, inhibition of its activity by modified heparin could attenuate metastatic progression. 26, 28 Notably, initial arrest and retention of Lewis lung carcinoma cells in the lungs was observed upon injection of LAC heparin. 44 These findings are in agreement with previous observations, that platelet-tumor cell aggregations contributed to increased tumor cell seeding to the lungs. 15, 36 In principle, all observations of metastasis attenuation by heparin or modified heparins in mice are in agreement with the possible inhibition of P-and/or L-selectin, but do not exclude involvement of heparanase from this process. Binding of P-and L-selectin to heparin depends on both sulfation and molecular size. 21, 22 Recent detailed structural analyses of heparin have shown that 2-O and 3-O-desulfation of heparin, as well as N-desulfation, limits binding by selectins, but are not of crucial importance for this interaction. 23 Conversely, 6-O-desulfation had a profound effect, indicating the essential role of this modification on binding. Finally, 2-O-and 3-O-desulfated heparin were shown to inhibit adhesion of human melanoma cells to P-selectin under flow in vitro. 24 
DISTINGUISHING HEPARANASE AND SELECTIN INHIBITORY ACTIVITY
Previously, a series of modified heparin derivatives of different degrees of sulfation, including 2-O-and 6-O-desulfated, N-acetylated, and so-called reduced oxyheparins, were prepared and analyzed for their heparanase inhibitory activity. 46 To identify derivatives with selectin-inhibitory activity, we tested these heparins for their potential to inhibit adhesion of LS180 carcinoma cells to immobilized selectins. To test the role of 6-O-sulfation for selectin recognition, two heparin derivatives with various degrees of desulfation were analyzed (Fig. 1) . The completely 6-O-desulfated heparin (6Odes-H) had profoundly reduced recognition by P-and L-selectin, which was in agreement with previous findings. 23 However, partially 6Odes-Hs (51% desulfated heparin [ 51 6Odes-H] or 42% desulfated heparin [ 42 6Odes-H]) were equally good inhibitors of P-selectin, as is heparin. In contrast, both 51 6Odes-H and 42 6Odes-H were poor inhibitors of L-selectin. Concentration that inhibits P-selectin by 50% (IC 50 ) of both partially 6-O-desulfated heparins was 30 mg/mL while for L-selectin IC 50 values were between 100-150 mg/mL. Therefore partial 6-O-desulfation of heparin did not affect its recognition by P-selectin. These results indicate that a certain degree of 6-O-sulfation is sufficient for P-selectin recognition, which is in agreement with the length dependence of heparin recognition. 21, 22 The reduced L-selectin inhibitory activity of partially 6Odes-Hs indicates a different binding of these preparations compared with P-selectin. 23 The inhibition of heparanase by modified heparins was shown previously to attenuate experimental metastasis. 11 Given that partially 6Odes-Hs are also potent inhibitors of heparanase, 46 these derivatives are not suitable for delineation of metastatic activity of heparin with respect to heparanase and selectin inhibition. Taken together, currently identified heparin derivatives with heparanase-inhibitory activity are efficient inhibitors of P-and/or L-selectin as well. Additional exploration of heparin derivatives will enable mechanistic analysis of the metastatic potential of heparin and will identify the relevance of heparanase and/or selectin-mediated interactions in this process.
CONCLUSIONS
Evaluation of the role of heparin derivatives during metastasis further delineates the underlying mechanism(s) involved in this process. Although a complete dissection of all of the individual biological activities of heparin is very unlikely to be achieved, a better understanding of this process will help in the design of specific inhibitors for targeting cancer progression. Additional characterization of heparin biology in the context of cancer is necessary. However, the already described affects of heparin and LMWH on cancer progression, acting through modulation of many biological functions (e.g., coagulation, heparanase, angiogenesis, selectins, growth factors, etc.) would make heparin therapy beneficial for cancer patients. 47 The extensive experience with heparin and LMWH therapy for thrombotic indications is presenting a rationale for cancer treatments.
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